DelveInsight’s, “B-Cell Non-Hodgkin Lymphoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the B-Cell Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the B-Cell Non-Hodgkin Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive B-Cell Non-Hodgkin Lymphoma pipeline products in this space.

 

Stay ahead with the latest insights! Download DelveInsight’s comprehensive B-Cell Non-Hodgkin Lymphoma Pipeline Report to explore emerging therapies, key B-Cell Non-Hodgkin Lymphoma Companies, and future B-Cell Non-Hodgkin Lymphoma treatment landscapes @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook Report

 

Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report

• In February 2025:- Novartis Pharmaceuticals- This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
• In February 2025:- Regeneron Pharmaceuticals:- This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as ‘refractory’) or has returned (also known as ‘relapsed’). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.
• In February 2025:- Hoffmann-La Roche:- This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).
• In February 2025:- Bristol-Myers Squibb:- The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
• DelveInsight’s B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
• The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
• Promising B-Cell Non-Hodgkin Lymphoma Therapies such as Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.

 

Discover how the B-Cell Non-Hodgkin Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth B-Cell Non-Hodgkin Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ B-Cell Non-Hodgkin Lymphoma Clinical Trials and Studies

 

B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile

• Valemetostat: Daiichi Sankyo

Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.

 

• MB-106: Mustang Bio

MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.

 

• CB-010: Caribou Biosciences

CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.

 

• LP-284: Lantern Pharma

LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern’s RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.

 

The B-Cell Non-Hodgkin Lymphoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma Treatment.
• B-Cell Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.

 

Get a detailed analysis of the latest innovations in the B-Cell Non-Hodgkin Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ B-Cell Non-Hodgkin Lymphoma Unmet Needs

 

B-Cell Non-Hodgkin Lymphoma Companies

Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.

 

B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Download DelveInsight’s latest report to gain strategic insights into upcoming B-Cell Non-Hodgkin Lymphoma Therapies and key B-Cell Non-Hodgkin Lymphoma Developments @ B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives

 

Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report

• Coverage- Global
• B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
• Promising B-Cell Non-Hodgkin Lymphoma Therapies– Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.
• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Which companies are leading the race in B-Cell Non-Hodgkin Lymphoma drug development? Find out in DelveInsight’s exclusive B-Cell Non-Hodgkin Lymphoma Pipeline Report—access it now! @ B-Cell Non-Hodgkin Lymphoma Emerging Drugs and Major Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. B-Cell Non-Hodgkin Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. B-Cell Non-Hodgkin Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Valemetostat: Daiichi Sankyo
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CB-010: Caribou Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. B-Cell Non-Hodgkin Lymphoma Key Companies
21. B-Cell Non-Hodgkin Lymphoma Key Products
22. B-Cell Non-Hodgkin Lymphoma- Unmet Needs
23. B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
24. B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
25. B-Cell Non-Hodgkin Lymphoma Analyst Views
26. B-Cell Non-Hodgkin Lymphoma Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cart-cell-therapy-competitive-landscape